We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

128 hedge funds and large institutions have $980M invested in Aclaris Therapeutics in 2021 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 34 increasing their positions, 32 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

172% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 18

32% more funds holding

Funds holding: 97 → 128 (+31)

15% more call options, than puts

Call options by funds: $3.32M | Put options by funds: $2.88M

7% more ownership

Funds ownership: 87.68% → 94.68% (+7%)

6% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 32

14% less capital invested

Capital invested by funds: $1.14B → $980M (-$165M)

47% less funds holding in top 10

Funds holding in top 10: 15 → 8 (-7)

Holders
128
Holders Change
+31
Holders Change %
+31.96%
% of All Funds
2.23%
Holding in Top 10
8
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-46.67%
% of All Funds
0.14%
New
49
Increased
34
Reduced
32
Closed
18
Calls
$3.32M
Puts
$2.88M
Net Calls
+$440K
Net Calls Change
-$1.75M

Top Buyers

1
Wellington Management Group
Wellington Management Group
Massachusetts
+$87.8M
2
BlackRock
BlackRock
New York
+$51.2M
3
BI
BVF Inc
California
+$22.7M
4
State Street
State Street
Massachusetts
+$19.9M
5
Holocene Advisors
Holocene Advisors
New York
+$19.8M

Top Sellers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$27.3M
2
Invesco
Invesco
Georgia
-$20.2M
3
Renaissance Technologies
Renaissance Technologies
New York
-$12.6M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$8.54M
5
GTC
Ghost Tree Capital
New York
-$7.95M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$82.5M +$87.8M +3,866,420 +465%
VA
2
VR Adviser
New York
$80.1M +$19.2M +843,380 +23%
RSCM
3
Rock Springs Capital Management
Maryland
$66.1M +$4.39M +193,120 +5%
FCMI
4
Foresite Capital Management IV
California
$59.7M – – –
BlackRock
5
BlackRock
New York
$56.9M +$51.2M +2,254,173 +229%
Vanguard Group
6
Vanguard Group
Pennsylvania
$45.1M +$10.2M +448,919 +21%
Renaissance Technologies
7
Renaissance Technologies
New York
$42.7M -$12.6M -554,600 -19%
Adage Capital Partners
8
Adage Capital Partners
Massachusetts
$35.1M -$27.3M -1,200,000 -38%
CAM
9
Cormorant Asset Management
Massachusetts
$35.1M – – –
FCMI
10
Foresite Capital Management III
California
$34.3M – – –
Fidelity Investments
11
Fidelity Investments
Massachusetts
$29.7M +$4.34M +191,000 +13%
CC
12
Commodore Capital
New York
$29.3M +$14.6M +640,903 +62%
PHP
13
Parkman Healthcare Partners
Connecticut
$26.4M -$4.72M -207,676 -12%
Holocene Advisors
14
Holocene Advisors
New York
$24.6M +$19.8M +872,509 +166%
VC
15
Vivo Capital
California
$24.1M -$6.2M -272,935 -17%
FCMV
16
Foresite Capital Management V
California
$22.1M – – –
Citadel Advisors
17
Citadel Advisors
Florida
$21.6M -$2.27M -99,956 -8%
State Street
18
State Street
Massachusetts
$18.8M +$19.9M +877,272 +455%
BI
19
BVF Inc
California
$17.6M +$22.7M +1,000,000 New
PA
20
Perceptive Advisors
New York
$14.9M +$4.54M +200,000 +31%
SB
21
Samsara BioCapital
California
$13.9M -$5.19M -228,441 -22%
Geode Capital Management
22
Geode Capital Management
Massachusetts
$12.6M +$7.77M +341,893 +91%
LGM
23
Logos Global Management
California
$11.9M +$15.3M +675,000 New
ACM
24
Aisling Capital Management
New York
$11.1M – – –
Assenagon Asset Management
25
Assenagon Asset Management
Luxembourg
$10.1M +$12.6M +556,283 +2,702%
1
2 3 4 5

ACRS Hedge Fund Activity: Q2 2021 in Review

128 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q2 2021, worth a combined $980M — down 14% from $1.14B a quarter earlier.

Buyers outnumbered sellers: 49 funds opened new ACRS positions and 18 closed out — a net gain of 31 holders — while 34 added to existing stakes and 32 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $87.8M. The largest seller was Adage Capital Partners, cutting an estimated $27.3M.

  • 128 institutional investors held Aclaris Therapeutics (ACRS) as of Q2 2021, up from 97 in Q1 2021.
  • Funds reported $980M of Aclaris Therapeutics stock for Q2 2021, down 14% quarter-over-quarter.
  • 49 funds opened new Aclaris Therapeutics positions in Q2 2021 and 18 closed out, a net change of +31 holders.
  • The largest Aclaris Therapeutics buyer in Q2 2021 was Wellington Management Group, an estimated $87.8M added.
  • The largest Aclaris Therapeutics seller in Q2 2021 was Adage Capital Partners, an estimated $27.3M sold.

Based on aggregated 13F filings for Q2 2021.